Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.65 |
| ▸ | MAOA | P21397 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578947 | 0.92 | MAOB (0.75) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL1664699 | 0.89 | MAOA (0.75) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL7145158 | 0.88 | MAOB (0.61) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL5552613 | 0.88 | MAOB (0.65) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL31388310 | 0.88 | MAOB (0.65) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL5883252 | 0.87 | MAOA (0.50) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL16406719 | 0.84 | MAOB (0.65) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL1853898 | 0.84 | MAOB (0.69) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL273282 | 0.83 | ALDH1A1 (0.47) | MAOBMAOARELASMN1; SMN2KDM4E | |
| SCHEMBL16990010 | 0.81 | MAOB (0.65) | MAOBMAOAMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
| CN-1115330-C | N- (4-amidinophenyl) glycinamide derivatives | HOFFMANN LA ROCHE (CH) | 2003-07-23 | — | — | CN | disclosed |
| EP-0921116-B1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| CN-1224714-A | N- (4-amidinophenyl) glycinamide derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-04 | — | — | CN | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | MAOB 704/4885MAOA 1115/4885MEN1 1001/4885 |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | SSTR5, SSTR3, NPY5R | MAOB 781/4885MAOA 1150/4885MEN1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.